NewAmsterdam Pharma

NAMS

Market cap $2.72B

Overview Fund Activity

24.19 USD

-2.41

9.06%

At close Updated Sep 12, 4:00 PM EDT

1 day

-9.06%

5 days

-9.26%

1 month

-3.24%

3 months

15.03%

6 months

3.55%

Year to date

-6.82%

1 year

51.19%

5 years

133.72%

10 years

133.72%

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

93% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 30

25% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 20

3% more funds holding

Funds holding: 126 [Q1] → 130 (+4) [Q2]

2.41% more ownership

Funds ownership: 101.24% [Q1] → 103.65% (+2.41%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]

8% less capital invested

Capital invested by funds: $2.28B [Q1] → $2.11B (-$171M) [Q2]

72% less call options, than puts

Call options by funds: $1.18M | Put options by funds: $4.16M

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$27

12% upside

Avg. target

$38

58% upside

High target

$45

86% upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Wells Fargo Yanan Zhu	$45	Overweight Initiated	25 Aug 2025
RBC Capital Leonid Timashev	$39	Outperform Maintained	7 Aug 2025
Goldman Sachs Asad Haider	$27	Neutral Initiated	17 Jul 2025
Citigroup Geoff Meacham	$42	Buy Initiated	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about NAMS published over the past 30 days

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Michael Davidson - CEO, President & Executive Board Member Mayur Somaiya - Chief Financial Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director All right.

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional pooled safety and efficacy data from the pivotal Phase 3 BROADWAY and BROOKLYN trials at the European Society of Cardiology Congress (ESC), taking place August 29 – September 1, 2025 in Madrid, Spain.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development.

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia -- -- NewAmsterdam entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in the Menarini Territory and up to an additional €833 million upon the achievement of various clinical, regulatory and commercial milestones --

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

The Motley Fool

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

Zacks Investment Research

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.52.

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – BROADWAY Alzheimer's disease analysis presented at AAIC 2025 showed obicetrapib significantly reduced plasma p-tau217 levels versus placebo in both the full analysis set and in ApoE4 carriers, over 12 months, with favorable trends observed in additional Alzheimer's biomarkers – NAARDEN, The Netherlands and MIAMI, Aug. 06, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended June 30, 2025 and provided a corporate update.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as a potential novel, upstream approach to Alzheimer's prevention –

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present full data from the prespecified Alzheimer's Disease (AD) biomarker analyses in the BROADWAY clinical trial (NCT05142722) in a late-breaking oral presentation at the Alzheimer's Association International Conference (AAIC), being held July 30, 2025 in Toronto, Canada.

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer's disease biomarker in both the full ITT population (p

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

See News Rankings

Charts implemented using Lightweight Charts™